Timing is everything for docetaxel therapy

Nature Reviews Urology

Volumn 10, Issue 3, 2013, Pages 123-

  Payton, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL; LUTEINIZING HORMONE AGONIST; UNCLASSIFIED DRUG;

ALOPECIA; ANDROGEN DEPRIVATION THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; NEUTROPENIA; NOTE; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SENSORY NEUROPATHY; TREATMENT OUTCOME;

EID: 84875214031     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.12     Document Type: Note

References (2)

1. Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol. doi:10.1016/S1470-2045(12)70560-0
2. Kellokumpu-Lehtinen, P. L. et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: A randomised, phase 3 trial. Lancet Oncol. doi:10.1016/S1470-2045(12)70537-5